Highlights
KLSE: PHARMA (7081)       PHARMANIAGA BHD MAIN : Health Care
Last Price Today's Change   Day's Range   Trading Volume
5.16   -0.01 (0.19%)  5.05 - 5.18  109,300
Analyze this stock with MQ Trader system

Financials


Market Cap: 1,350 Million

Market Cap 1,350 Million
NOSH 262 Million

Latest Audited Result:  31-Dec-2019

Latest Audited Result: 31-Dec-2019
Announcement Date 19-Jun-2020
Next Audited Result: 31-Dec-2020
Est. Ann. Date: 19-Jun-2021
Est. Ann. Due Date: 29-Jun-2021

Latest Quarter:  30-Sep-2020 [#3]

Latest Quarter: 30-Sep-2020 [#3]
Announcement Date 19-Nov-2020
Next Quarter: 31-Dec-2020
Est. Ann. Date: 20-Feb-2021
Est. Ann. Due Date: 01-Mar-2021
QoQ | YoY   -85.55%  |    199.79%

Annual (Unaudited) ( EPS: -57.02, P/E: -9.05 )

Revenue | NP to SH 2,820,530  |  -149,219
RPS | P/RPS 1,077.75 Cent  |  0.48
EPS | P/E | EY -57.02 Cent  |  -9.05  |  -11.05%
DPS | DY | Payout % 8.47 Cent  |  1.64%  |  - %
NAPS | P/NAPS 1.29  |  4.01
YoY   -451.37%
NP Margin | ROE -5.30%  |  -44.33%
F.Y. | Ann. Date 31-Dec-2019  |  20-Feb-2020

T4Q Result ( EPS: -55.32, P/E: -9.33 )

Revenue | NP to SH 2,806,171  |  -144,778
RPS | P/RPS 1,072.26 Cent  |  0.48
EPS | P/E | EY -55.32 Cent  |  -9.33  |  -10.72%
DPS | DY | Payout % 9.98 Cent  |  1.93%  |  - %
NAPS | P/NAPS 1.32  |  3.91
QoQ | YoY   0.66%  |    -528.13%
NP Margin | ROE -5.18%  |  -41.96%
F.Y. | Ann. Date 30-Sep-2020  |  19-Nov-2020

Annualized Result ( EPS: 17.23, P/E: 29.95 )

Revenue | NP to SH 2,787,317  |  45,093
RPS | P/RPS 1,065.06 Cent  |  0.48
EPS | P/E | EY 17.23 Cent  |  29.95  |  3.34%
DPS | DY | Payout % -
NAPS | P/NAPS -
QoQ | YoY   -30.36%  |    15.12%
NP Margin | ROE 1.59%  |  13.07%
F.Y. | Ann. Date 30-Sep-2020  |  19-Nov-2020


Hints :
Click the QoQ or YoY on table to view the QoQ or YoY Financial Result page.

Click here to modify the Visible Columns.

Date Financial Result Financial Ratio Per Share Item Performance Valuation (End of Quarter) Valuation (Ann. Date)
F.Y. Ann. Date Quarter # Revenue PBT NP NP to SH Div Net Worth Div Payout % NP Margin ROE NOSH RPS Adj. RPS EPS Adj. EPS DPS Adj. DPS NAPS Adj. NAPS QoQ YoY EOQ Date EOQ Price EOQ P/RPS EOQ P/EPS EOQ P/NAPS EOQ EY EOQ DY ANN Date ANN Price ANN P/RPS ANN P/EPS ANN P/NAPS ANN EY ANN DY
31-Dec-2020 19-Nov-2020 30-Sep-2020 3 624,804 4,093 1,294 1,442 3,920 345,040 271.91% 0.21% 0.42% 261,394 239.03 238.74 0.55 0.55 1.50 1.50 1.3200 1.32   -85.55%   199.79% 30-Sep-2020 4.32 1.81 783.09 3.27 0.13% 0.35% 19-Nov-2020 5.72 2.39 1,036.87 4.33 0.10% 0.26%
31-Dec-2020 19-Aug-2020 30-Jun-2020 2 645,763 14,326 9,607 9,979 6,530 357,891 65.45% 1.49% 2.79% 261,235 247.20 246.75 3.82 3.81 2.50 2.50 1.3700 1.37   -55.45%   7.52% 30-Jun-2020 2.22 0.90 58.12 1.62 1.72% 1.13% 19-Aug-2020 4.42 1.79 115.71 3.23 0.86% 0.57%
31-Dec-2020 19-May-2020 31-Mar-2020 1 819,921 30,880 22,415 22,399 15,673 350,047 69.98% 2.73% 6.40% 261,229 313.87 313.30 8.57 8.56 6.00 5.99 1.3400 1.34   112.54%   14.18% 31-Mar-2020 1.26 0.40 14.69 0.94 6.81% 4.76% 19-May-2020 1.88 0.60 21.93 1.40 4.56% 3.19%
31-Dec-2019 20-Feb-2020 31-Dec-2019 4 715,683 -238,474 -178,733 -178,598 - 336,573 - % -24.97% -53.06% 260,910 274.30 273.47 -68.45 -68.24 0.00 0.00 1.2900 1.29   -37,230.56%   -4,125.20% 31-Dec-2019 2.06 0.75 -3.01 1.60 -33.23% 0.00% 20-Feb-2020 2.04 0.74 -2.98 1.58 -33.55% 0.00%
31-Dec-2019 20-Nov-2019 30-Sep-2019 3 716,849 3,885 376 481 - 516,387 - % 0.05% 0.09% 260,802 274.86 273.91 0.18 0.18 0.00 0.00 1.9800 1.97   -94.82%   -96.80% 30-Sep-2019 2.44 0.89 1,322.99 1.23 0.08% 0.00% 20-Nov-2019 2.21 0.80 1,198.28 1.12 0.08% 0.00%
31-Dec-2019 23-Aug-2019 30-Jun-2019 2 601,890 12,481 9,262 9,281 6,514 518,564 70.19% 1.54% 1.79% 260,585 230.98 229.99 3.56 3.55 2.50 2.49 1.9900 1.98   -52.69%   72.06% 28-Jun-2019 2.84 1.23 79.74 1.43 1.25% 0.88% 23-Aug-2019 2.66 1.15 74.69 1.34 1.34% 0.94%
31-Dec-2019 16-May-2019 31-Mar-2019 1 786,108 30,243 19,648 19,617 15,630 528,825 79.68% 2.50% 3.71% 260,505 301.76 300.38 7.53 7.50 6.00 5.97 2.0300 2.02   342.12%   11.55% 29-Mar-2019 2.27 0.75 30.14 1.12 3.32% 2.64% 16-May-2019 2.36 0.78 31.34 1.16 3.19% 2.54%
31-Dec-2018 21-Feb-2019 31-Dec-2018 4 596,644 11,940 4,570 4,437 5,202 509,862 117.26% 0.77% 0.87% 260,134 229.36 227.98 1.71 1.70 2.00 1.99 1.9600 1.95   -70.52%   -79.55% 31-Dec-2018 2.78 1.21 162.99 1.42 0.61% 0.72% 21-Feb-2019 2.76 1.20 161.81 1.41 0.62% 0.72%
31-Dec-2018 19-Nov-2018 30-Sep-2018 3 587,660 17,603 15,305 15,051 13,000 522,618 86.38% 2.60% 2.88% 260,009 226.02 224.55 5.79 5.75 5.00 4.97 2.0100 2.00   179.03%   320.42% 28-Sep-2018 2.89 1.28 49.93 1.44 2.00% 1.73% 19-Nov-2018 3.09 1.37 53.38 1.54 1.87% 1.62%
31-Dec-2018 17-Aug-2018 30-Jun-2018 2 582,729 11,970 5,766 5,394 10,392 519,642 192.67% 0.99% 1.04% 259,821 224.28 222.67 2.08 2.06 4.00 3.97 2.0000 1.99   -69.33%   -43.34% 29-Jun-2018 2.88 1.28 138.73 1.44 0.72% 1.39% 17-Aug-2018 3.11 1.39 149.80 1.56 0.67% 1.29%
31-Dec-2018 16-May-2018 31-Mar-2018 1 617,923 28,707 17,589 17,586 12,991 524,838 73.87% 2.85% 3.35% 259,821 237.83 236.11 6.77 6.72 5.00 4.96 2.0200 2.01   -18.96%   -7.07% 30-Mar-2018 4.28 1.80 63.23 2.12 1.58% 1.17% 16-May-2018 4.07 1.71 60.13 2.01 1.66% 1.23%
31-Dec-2017 27-Feb-2018 31-Dec-2017 4 613,196 19,866 22,088 21,700 15,573 526,888 71.77% 3.60% 4.12% 259,551 236.25 234.31 8.36 8.29 6.00 5.95 2.0300 2.01   506.15%   2,695.69% 29-Dec-2017 4.60 1.95 55.02 2.27 1.82% 1.30% 27-Feb-2018 4.04 1.71 48.32 1.99 2.07% 1.49%
31-Dec-2017 15-Nov-2017 30-Sep-2017 3 574,503 15,271 3,890 3,580 12,973 531,892 362.37% 0.68% 0.67% 259,460 221.42 219.52 1.38 1.37 5.00 4.96 2.0500 2.03   -62.39%   -72.59% 29-Sep-2017 4.14 1.87 300.05 2.02 0.33% 1.21% 15-Nov-2017 3.82 1.73 276.85 1.86 0.36% 1.31%
31-Dec-2017 16-Aug-2017 30-Jun-2017 2 517,967 10,150 9,751 9,520 10,376 542,147 108.99% 1.88% 1.76% 259,400 199.68 197.92 3.67 3.64 4.00 3.96 2.0900 2.07   -49.69%   -36.51% 30-Jun-2017 4.58 2.29 124.80 2.19 0.80% 0.87% 16-Aug-2017 4.19 2.10 114.17 2.00 0.88% 0.95%
31-Dec-2017 16-May-2017 31-Mar-2017 1 618,294 27,777 19,258 18,923 10,368 544,360 54.79% 3.11% 3.48% 259,219 238.52 236.26 7.30 7.23 4.00 3.96 2.1000 2.08   2,363.52%   2.96% 31-Mar-2017 4.89 2.05 66.99 2.33 1.49% 0.82% 16-May-2017 4.72 1.98 64.66 2.25 1.55% 0.85%
31-Dec-2016 21-Feb-2017 31-Dec-2016 4 582,816 4,069 -900 -836 7,773 531,169 - % -0.15% -0.16% 259,107 224.93 222.70 -0.32 -0.32 3.00 2.97 2.0500 2.03   -106.40%   -105.20% 30-Dec-2016 5.30 2.36 -1,642.66 2.59 -0.06% 0.57% 21-Feb-2017 5.12 2.28 -1,586.88 2.50 -0.06% 0.59%
31-Dec-2016 21-Nov-2016 30-Sep-2016 3 515,215 19,923 12,648 13,061 10,365 531,250 79.37% 2.45% 2.46% 259,146 198.81 196.87 5.04 4.99 4.00 3.96 2.0500 2.03   -12.90%   -34.60% 30-Sep-2016 5.58 2.81 110.71 2.72 0.90% 0.72% 21-Nov-2016 5.70 2.87 113.10 2.78 0.88% 0.70%
31-Dec-2016 19-Aug-2016 30-Jun-2016 2 531,796 21,487 15,641 14,995 12,949 524,177 86.36% 2.94% 2.86% 258,981 205.34 203.20 5.79 5.73 5.00 4.95 2.0240 2.00   -18.41%   -7.54% 30-Jun-2016 5.50 2.68 94.99 2.72 1.05% 0.91% 19-Aug-2016 5.62 2.74 97.06 2.78 1.03% 0.89%
31-Dec-2016 13-May-2016 31-Mar-2016 1 559,195 26,538 18,470 18,379 10,354 515,906 56.34% 3.30% 3.56% 258,859 216.02 213.67 7.10 7.02 4.00 3.96 1.9930 1.97   14.43%   -42.19% 31-Mar-2016 5.76 2.67 81.13 2.89 1.23% 0.69% 13-May-2016 5.60 2.59 78.87 2.81 1.27% 0.71%
31-Dec-2015 15-Feb-2016 31-Dec-2015 4 680,150 23,717 16,041 16,062 18,134 529,786 112.90% 2.36% 3.03% 259,064 262.54 259.89 6.20 6.14 7.00 6.93 2.0450 2.02   -19.57%   -56.23% 31-Dec-2015 6.36 2.42 102.58 3.11 0.97% 1.10% 15-Feb-2016 6.19 2.36 99.84 3.03 1.00% 1.13%
31-Dec-2015 26-Nov-2015 30-Sep-2015 3 524,413 25,337 19,975 19,971 23,312 534,373 116.73% 3.81% 3.74% 259,027 202.45 200.38 7.71 7.63 9.00 8.91 2.0630 2.04   23.15%   33.54% 30-Sep-2015 6.50 3.21 84.31 3.15 1.19% 1.38% 26-Nov-2015 6.50 3.21 84.31 3.15 1.19% 1.38%
31-Dec-2015 17-Aug-2015 30-Jun-2015 2 512,845 25,056 16,642 16,217 18,134 528,477 111.82% 3.25% 3.07% 259,057 197.97 195.96 6.26 6.20 7.00 6.93 2.0400 2.02   -48.99%   1.51% 30-Jun-2015 7.13 3.60 113.90 3.50 0.88% 0.98% 17-Aug-2015 5.65 2.85 90.26 2.77 1.11% 1.24%
31-Dec-2015 18-May-2015 31-Mar-2015 1 471,904 38,612 31,926 31,794 18,123 528,173 57.00% 6.77% 6.02% 258,908 182.27 180.32 12.28 12.15 7.00 6.93 2.0400 2.02   -13.36%   21.27% 31-Mar-2015 6.00 3.29 48.86 2.94 2.05% 1.17% 18-May-2015 6.91 3.79 56.27 3.39 1.78% 1.01%
31-Dec-2014 23-Feb-2015 31-Dec-2014 4 627,103 37,854 36,621 36,697 31,055 525,351 84.63% 5.84% 6.99% 258,794 242.32 239.62 14.18 14.02 12.00 11.87 2.0300 2.01   145.38%   76.32% 31-Dec-2014 4.58 1.89 32.30 2.26 3.10% 2.62% 23-Feb-2015 5.28 2.18 37.24 2.60 2.69% 2.27%
31-Dec-2014 21-Nov-2014 30-Sep-2014 3 502,086 24,945 15,001 14,955 20,698 507,124 138.41% 2.99% 2.95% 258,737 194.05 191.85 5.78 5.71 8.00 7.91 1.9600 1.94   -6.38%   298.69% 30-Sep-2014 4.63 2.39 80.10 2.36 1.25% 1.73% 21-Nov-2014 4.45 2.29 76.99 2.27 1.30% 1.80%
31-Dec-2014 21-Aug-2014 30-Jun-2014 2 525,072 24,622 15,957 15,975 10,356 502,293 64.83% 3.04% 3.18% 258,914 202.80 200.63 6.17 6.10 4.00 3.96 1.9400 1.92   -39.07%   172.38% 30-Jun-2014 4.61 2.27 74.72 2.38 1.34% 0.87% 21-Aug-2014 4.62 2.28 74.88 2.38 1.34% 0.87%
31-Dec-2014 14-May-2014 31-Mar-2014 1 468,672 38,159 26,646 26,217 10,352 515,022 39.49% 5.69% 5.09% 258,805 181.09 179.08 10.13 10.02 4.00 3.96 1.9900 1.97   25.96%   5.84% 31-Mar-2014 4.46 2.46 44.03 2.24 2.27% 0.90% 14-May-2014 4.70 2.60 46.40 2.36 2.16% 0.85%
31-Dec-2013 24-Feb-2014 31-Dec-2013 4 567,860 33,007 21,267 20,813 16,049 486,672 77.11% 3.75% 4.28% 258,868 219.36 216.98 8.04 7.95 6.20 6.13 1.8800 1.86   454.87%   362.33% 31-Dec-2013 4.45 2.03 55.35 2.37 1.81% 1.39% 24-Feb-2014 4.29 1.96 53.36 2.28 1.87% 1.45%
31-Dec-2013 19-Nov-2013 30-Sep-2013 3 440,807 13,461 4,170 3,751 7,760 473,402 206.90% 0.95% 0.79% 258,689 170.40 168.44 1.45 1.43 3.00 2.97 1.8300 1.81   -36.04%   -85.14% 30-Sep-2013 4.82 2.83 332.41 2.63 0.30% 0.62% 19-Nov-2013 4.72 2.77 325.52 2.58 0.31% 0.64%
31-Dec-2013 16-Aug-2013 30-Jun-2013 2 437,633 9,605 6,171 5,865 8,810 480,568 150.22% 1.41% 1.22% 258,370 169.38 167.22 2.27 2.24 3.41 3.37 1.8600 1.84   -76.32%   -62.67% 28-Jun-2013 4.49 2.65 197.80 2.41 0.51% 0.76% 16-Aug-2013 4.66 2.75 205.29 2.51 0.49% 0.73%
31-Dec-2013 15-May-2013 31-Mar-2013 1 500,339 36,924 25,153 24,771 8,825 484,829 35.63% 5.03% 5.11% 117,676 425.18 191.18 21.05 9.47 7.50 3.37 4.1200 1.85   412.21%   -13.64% 29-Mar-2013 8.26 1.94 39.24 2.00 2.55% 0.91% 15-May-2013 9.26 2.18 43.99 2.25 2.27% 0.81%
31-Dec-2012 18-Feb-2013 31-Dec-2012 4 482,404 4,248 -7,468 -7,934 11,771 472,037 - % -1.55% -1.68% 117,715 409.81 184.33 -6.74 -3.03 10.00 4.50 4.0100 1.80   -131.43%   -166.44% 31-Dec-2012 8.10 1.98 -120.18 2.02 -0.83% 1.23% 18-Feb-2013 7.80 1.90 -115.73 1.95 -0.86% 1.28%
31-Dec-2012 06-Nov-2012 30-Sep-2012 3 426,460 28,493 25,536 25,247 11,764 496,469 46.60% 5.99% 5.09% 117,646 362.49 162.95 21.46 9.65 10.00 4.50 4.2200 1.90   60.68%   133.53% 28-Sep-2012 7.55 2.08 35.18 1.79 2.84% 1.32% 06-Nov-2012 8.25 2.28 38.44 1.95 2.60% 1.21%
31-Dec-2012 08-Aug-2012 30-Jun-2012 2 456,737 27,618 16,077 15,713 8,827 481,394 56.18% 3.52% 3.26% 117,700 388.05 174.52 13.35 6.00 7.50 3.37 4.0900 1.84   -45.22%   12.88% 29-Jun-2012 10.18 2.62 76.25 2.49 1.31% 0.74% 08-Aug-2012 8.83 2.28 66.14 2.16 1.51% 0.85%
31-Dec-2012 03-May-2012 31-Mar-2012 1 446,745 42,955 29,061 28,685 8,824 474,161 30.76% 6.51% 6.05% 117,657 379.70 170.71 24.38 10.96 7.50 3.37 4.0300 1.81   140.20%   85.26% 30-Mar-2012 5.90 1.55 24.20 1.46 4.13% 1.27% 03-May-2012 5.90 1.55 24.20 1.46 4.13% 1.27%
31-Dec-2011 22-Feb-2012 31-Dec-2011 4 367,786 16,368 12,182 11,942 35,296 514,153 295.57% 3.31% 2.32% 117,655 312.60 140.53 10.15 4.56 30.00 13.49 4.3700 1.96   10.46%   629.34% 30-Dec-2011 5.36 1.71 52.81 1.23 1.89% 5.60% 22-Feb-2012 5.90 1.89 58.13 1.35 1.72% 5.08%
31-Dec-2011 01-Nov-2011 30-Sep-2011 3 371,432 15,646 10,959 10,811 - 464,092 - % 2.95% 2.33% 106,933 347.35 141.93 10.11 4.13 0.00 0.00 4.3400 1.77   -22.33%   25.91% 30-Sep-2011 5.90 1.70 58.36 1.36 1.71% 0.00% 01-Nov-2011 5.90 1.70 58.36 1.36 1.71% 0.00%
31-Dec-2011 10-Aug-2011 30-Jun-2011 2 396,435 19,380 14,045 13,920 - 451,517 - % 3.54% 3.08% 106,994 370.52 151.48 13.01 5.32 0.00 0.00 4.2200 1.73   -10.10%   -5.61% 30-Jun-2011 5.90 1.59 45.35 1.40 2.21% 0.00% 10-Aug-2011 5.90 1.59 45.35 1.40 2.21% 0.00%
31-Dec-2011 13-May-2011 31-Mar-2011 1 385,328 21,792 15,599 15,484 - 437,661 - % 4.05% 3.54% 107,007 360.09 147.24 14.47 5.92 0.00 0.00 4.0900 1.67   786.35%   66.37% 31-Mar-2011 5.73 1.59 39.60 1.40 2.53% 0.00% 13-May-2011 5.05 1.40 34.90 1.23 2.87% 0.00%
31-Dec-2010 25-Feb-2011 31-Dec-2010 4 376,116 -2,701 -1,952 -2,256 - 421,262 - % -0.52% -0.54% 106,919 351.78 143.72 -2.11 -0.86 0.00 0.00 3.9400 1.61   -126.28%   -110.29% 30-Dec-2010 5.31 1.51 -251.66 1.35 -0.40% 0.00% 25-Feb-2011 5.35 1.52 -253.55 1.36 -0.39% 0.00%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.


NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ Δ & YoY Δ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.


Trade this stock for as low as 0.05% brokerage. Find out more.
  2 people like this.
 
MZM2511 and has an overall efficacy of 50.4 percent in Brazil's final-stage trials.
13/01/2021 1:35 PM
MZM2511 1. China’s Sinovac COVID-19 Vaccine Less Effective than Initially Thought

Source: https://www.voanews.com/covid-19-pandemic/chinas-sinovac-covid-19-vaccine-less-effective-initially-thought

2. Sinovac's Covid-19 vaccine 78% effective in late-stage trial in Brazil — source
Source: https://www.theedgemarkets.com/article/sinovacs-covid19-vaccine-78-effective-latestage-trial-brazil-%E2%80%94-source

3. New Brazil data shows disappointing 50.4% efficacy for China's CoronaVac vaccine
Source: https://www.theedgemarkets.com/article/new-brazil-data-shows-disappointing-504-efficacy-chinas-coronavac-vaccine

4. Coronavirus: Scientists concerned by way data from Chinese drug firm Sinovac’s vaccine trials is coming out

Source: https://sg.news.yahoo.com/coronavirus-scientists-concerned-way-data-140100178.html
13/01/2021 1:37 PM
Loading This vaccine is like add ons in video games,

need to 'stack' to become stronger ..

1dose 50% + 1dose 50% = 100%

no limit ..
13/01/2021 1:43 PM
MZM2511 Better give 3 doses. 50% + 50% + 50% = 150% He He
I personally don't want to have this type of vaccine.....
13/01/2021 1:46 PM
BennyWhittman Bolih U-Turn lagi....

https://www.malaymail.com/news/malaysia/2021/01/13/khairy-malaysia-to-study-sinovac-clinical-trial-data-before-approving-covid/1940067
13/01/2021 5:34 PM
MZM2511 Wariness in Indonesia as Chinese Sinovac COVID-19 jabs start.

"I'm not rejecting vaccines, I'm rejecting Sinovac's," said Yusdeny Lanasakti, an East Java doctor who is worried about the vaccine's efficacy.

Source: https://uk.news.yahoo.com/wariness-indonesia-chinese-sinovac-covid-080953468.html
13/01/2021 5:46 PM
Financier Inix is venturing into the vaccine. This puts Inix in a position better than those of other glove manufacturers.

https://www.bursamalaysia.com/market_information/announcements/company...
13/01/2021 5:51 PM
BennyWhittman Who? Never heard of them. Too insignificant.
13/01/2021 6:07 PM
emc2garylow 50% 20% or 5% only u still need to pay the price for 12 millions dose lor, 50 % u pay for 6 millions dose only mei.... Later u go buy burger and say abang ini burger tak sedap la, bayar separuh boleh bang?
13/01/2021 9:13 PM
chuosyew https://www.enanyang.my/%E5%BE%B7%E5%9B%BD%E4%B9%8B%E5%A3%B0/%E5%B7%B4%E8%A5%BF%E5%86%8D%E8%B0%83%E9%99%8D%E7%A7%91%E5%85%B4%E7%96%AB%E8%8B%97%E4%BF%9D%E6%8A%A4%E5%8A%9B-%E4%B8%AD%E5%AE%98%E5%AA%92%E6%80%A5%E2%80%9C%E6%8A%A4%E8%88%AA%E2%80%9D
13/01/2021 9:46 PM
chuosyew please read, only found mandarin. sinovac vaccine ia safe. the trial at brasil is use for frontliner.
13/01/2021 9:48 PM
Miche87 tmr limit down.. gg
13/01/2021 10:08 PM
TecStock https://news.cgtn.com/news/2021-01-13/China-s-COVID-19-vaccine-may-be-new-candidate-in-EU-Italy-X1umZpDoTm/index.html
13/01/2021 10:17 PM
chuosyew https://news.cgtn.com/news/2021-01-13/CEO-Sinovac-COVID-19-vaccine-safe-and-efficient-X1ac7YSHcY/share_amp.html
13/01/2021 10:53 PM
kancil850 My friend in jakarta told me today sinovac jab is starting to be administered over in his city, but he is not part of as he is older, over 60 yo.
13/01/2021 10:58 PM
BennyWhittman Water is safe, try water and it's cheap.

Safe doesn't mean it's EFFECTIVE. Damn it, people's lives at stake and they still want to profit on fake meds.

The term safe means it doesn't have adverse side effect. The main criteria is to PROTECT and do it's job well, with efficacy above 90%

Those who want to have FALSE PROTECTION, please line up for this shot.
14/01/2021 8:28 AM
Goldberg Read this article: Evidence that prove JP Morgan's Jeffrey Ng analyst report on Glove is irresponsible and materially full with false data

https://klse.i3investor.com/blogs/GillianTan/2021-01-14-story-h1539323...
14/01/2021 8:42 AM
BennyWhittman Anyone who believed the tales told by Investment Bankers duly DESERVED what they get. Suffer the consequences. JP also predicted TG to go down by 50% to RM3.50. Hogwash.
14/01/2021 1:07 PM
TecStock https://newsaf.cgtn.com/news/2021-01-14/Turkish-health-minister-gets-Sinovac-vaccine-jab-X1RW4FaqhW/index.html
14/01/2021 1:36 PM
chuosyew https://www.astroawani.com/berita-dunia/turkey-approves-chinabased-sinovac-vaccines-emergency-use-277713
14/01/2021 3:17 PM
pang72 Steady lo..
Vaccine mari..

Glove kena short
14/01/2021 4:41 PM
pang72 Kita tight tight vaccine
14/01/2021 4:41 PM
eyeHunter We refer to Pharma’s announcement dated 12 January 2021 in respect of the aforesaid matter.


In this connection, kindly furnish Bursa Securities with the following additional information for public release:



1) Whether PLS possesses the required expertise, knowhow and resources to manufacture the Covid-19 vaccine.

2) The tentative timeframe to enter into the Local Manufacturing Agreement and a Technology and Know-How License Agreement with SINOVAC LS.

3) The risks in relation to the manufacturing of the Covid-19 vaccine that PLS may be exposed to.

4) To elaborate the manner in which PLS intends to market and distribute the Covid-19 vaccine and whether any contract has been secured todate.

5) To specify the relevant authorities’ approvals required for the clinical trial of the Covid-19 vaccine and the manufacturing, distribution and sale of the Covid-19 vaccine in Malaysia together with the status of approval, where applicable.

6) The estimated total capital outlay or costs to be incurred and the source of funding for the manufacturing of Covid- 19 vaccine.



Please furnish Bursa Securities with your reply within one (1) market day from the date hereof.



Yours faithfully





Listing

Regulation
14/01/2021 6:44 PM
eyeHunter Where is the reply?
14/01/2021 6:45 PM
BennyWhittman Mr President aka Joyvest (paid trooper from Bintai and Solution forum), We didn't know that Pfizer-BioNTech Pharmceutical belongs to your father. If so, kindly expedite Malaysian' procurement.

KJ has announced that MOSTI is flexible and will not proceed if any Vaccines failed it's Standard and Efficiency. NPRA also have the CTIL certified prior to any APPROVALS.
14/01/2021 7:49 PM
BennyWhittman Where did he go? Tail between his legs also can run away so fast.
14/01/2021 7:54 PM
Zolan2020 no hope la. better run to dpharma.
14/01/2021 9:27 PM
shark3011 https://www.freemalaysiatoday.com/category/nation/2021/01/14/rm5mil-fine-and-jail-if-private-hospitals-say-no-to-covid-19-patients/
14/01/2021 9:40 PM
Godofgambler Wow pharma going to manufacture sinovac
vaccine locally? Well done!!!
14/01/2021 11:39 PM
Godofgambler Pharmaniaga said it had initiated negotiation for the local manufacturing agreement as well as the technology and know-how licence agreement with Sinovac LS, which are expected to be executed within one month
14/01/2021 11:47 PM
Sales Glove stock more valuable.....
15/01/2021 12:07 PM
cloudde I'm not sure if they're going to manufacture the vaccines but from the announcement, they managed to procure ready vaccines to be used and in bulk (for the fill and finish). Bear in mind that we're in a pandemic and that many high economic activities are under MCO. My guess is that the bulk of vaccines they've procured will also be allocated and prioritized to KKM and private hospitals.

Don't see this as a race between Pharma and Duopharma as even with PFE's and Sinovac's vaccines secured, we're still short to cover the target 80% population. And each person will require 2 doses. Profitability wise, this is a good additional mid-term revenue source for PHARMA and I don't see it going away anytime soon. Even with other vaccines supply, the fill and finish approach is still the most practical to reduce overall vaccines cost to users. I highly doubt PFE or others would allow manufacturing locally and not sure if it's feasible to transport huge bulk of PFE for fill and finish (imagine to ensure huge tanks at -80 degrees - such technological challenge)

I'm not privy to Duopharma's progress in securing vaccine supplies besides this old post. Anyone has updated information? It's kinda odd since KJ was seen as leading the negotiations for both companies but only announced for PHARMA. Did Duopharma's negotiation fell apart?

https://www.theedgemarkets.com/article/duopharma-ready-package-covid19-vaccines
15/01/2021 12:19 PM
BennyWhittman MOSTI have come out in defense of their choice in Sinovac's CoronaVac. As the reports of lower than earlier expected efficacy, perhaps they may have a second look. Otherwise, NPRA might need to properly scrutinise the CTIL from other countries, especially Brazil and now Indonesia. As for R&D and transfer of technology with local manufacturing, that would be a step too soon at the moment but still on the cards.

Pfizer's vaccine requirement for the cold chain transportation has been addressed by MOSTI with the recent purchase of some 55 units of deep freeze fridges. The vaccines would be most probably shipped in vials and require dilution in saline before shooting into arms. Should not be thawed for FnF. The genetic engineering technology for this vaccine may still not be transferable give the high end equipment, facilities and meticulous procedures.

Nobody hold privy to the GLCs roles and responsibilities in rolling out the vaccines. We are all having calculated definitions of their capabilities and on-going current services rendered to MOH. Coupled with the fact that MOSTI had announced their participation in the roll-out plans.
15/01/2021 1:06 PM
BennyWhittman The reason that Pharma is getting the chinese vaccine Contract is because they are the GLC which has been performing the logistic and deliveries to all Govt hospitals, penetrating even the rural jungle villages. As mentioned before, NO MIDDLEMAN. Some naysayers still don't seem to understand the context of commerce in business transactions.

Govt is buying the vaccine and bringing in Pharma to the table. It's not that Pharma has decided to buying the vaccine and sell it to the govt.

The govt approved the procurement and hand it to Pharma to facilitate the real and actual import and downstream exercise.

The same scenario would presumably be happening to Dpharma. With Pharma's re-purposing their FnF facility and hitting full capacities, Dpharma may be awarded the AZ or Sputnik V, although AZ seems higher possibility with their approved EUA status from UK, USA, Europe and many other countries.
15/01/2021 1:17 PM
flyborn Good explanation benny
Same principle of business happen in uae, whereby government purchases such vaccines and government agencies distribute to the uae people including ex.
Hopefully Pharmaniaga will get profits for that.
15/01/2021 7:12 PM
TecStock https://www.euroweeklynews.com/2021/01/15/norway-changes-vaccine-guidelines-after-23-deaths/
16/01/2021 3:23 PM
TecStock http://enapp.globaltimes.cn/#/article/1212939
16/01/2021 3:25 PM
Lifeunlimited https://www.klsescreener.com/v2/news/view/779047
16/01/2021 4:25 PM
eYuppie Will govt continue with Sinovac after reported only 50.3% efficacy in Brazil?
How about the Chinese vaccine Sinopharm? Cambodia PM is injecting the Sinopharm vaccine.
https://www.khmertimeskh.com/50804325/pm-i-will-get-the-covid-19-vaccine-first/
17/01/2021 7:31 PM
FortuneBlooming ha ha ha
17/01/2021 10:34 PM
FortuneBlooming Something fishy: Pfizer CEO not jabbing himself with Pfizer vaccine raises big questions

https://www.news18.com/amp/news/buzz/something-fishy-pfizer-ceo-not-getting-his-own-companys-covid-19-vaccine-raises-questions-3182408.html
17/01/2021 10:34 PM
FortuneBlooming What a big joker
17/01/2021 10:35 PM
FortuneBlooming What a jerk
17/01/2021 10:35 PM
Godofgambler https://www.google.com/amp/s/news.cgtn.com/news/2021-01-17/China-s-vaccine-can-cross-neutralize-different-COVID-strains-CNBG-X7DidHHXP2/share_amp.html
17/01/2021 10:57 PM
bigby7 China Vaccine 50% effective..
Now pfizer deaths..From 23 to 29 now
Scary oh..

Tomorrow market merah..


https://www.bloomberg.com/news/articles/2021-01-16/norway-vaccine-fata...
18/01/2021 12:12 AM
eYuppie https://www.scmp.com/coronavirus/europe/article/3118087/coronavirus-norway-raises-concern-over-pfizer-jabs-elderly

Norway has expressed increasing concern about the safety of the Pfizer-BioNTech vaccine on elderly people with serious underlying health conditions after raising an estimate of the "number who died after receiving inoculations to 29".
18/01/2021 12:42 AM
Godofgambler https://www.reuters.com/article/us-health-coronavirus-brazil/brazil-clears-emergency-use-of-sinovac-astrazeneca-vaccines-shots-begin-idUSKBN29M0M3
18/01/2021 7:31 AM
Godofgambler https://www.bbc.com/news/uk-55698132
18/01/2021 7:33 AM
eYuppie https://www.khmertimeskh.com/50804460/why-were-us-media-silent-on-pfizer-vaccine-deaths/
Why were US media silent on Pfizer vaccine deaths?
18/01/2021 12:42 PM
uppvestor march start vaccination dy... time to in
18/01/2021 6:21 PM